Remote Digital Smell Test to Detect Early Signs of Alzheimers and Cognitive Changes in Adults

What this Trial Is About

Researchers are evaluating the AROMHA Brain Health Test as a way to measure the sense of smell in adults with Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, and healthy age-matched controls. The study aims to determine if this test can serve as a noninvasive and cost-effective biomarker to help distinguish neurodegenerative disorders from normal aging. This could lead to better early diagnosis and monitoring of these conditions. Participants will complete the AROMHA Brain Health Smell Test, which takes about 45 minutes and is self-administered at home. It involves peeling and sniffing labels on physical smell cards and answering questions through a web-based app about the odors. The test measures odor intensity, identification, discrimination, and episodic olfactory memory, but participants will not receive their individual test results. During the study, researchers will collect data from the smell test and monitor participants olfactory abilities. The study includes adults aged 18 to 100 years from clinical and community settings, including those diagnosed with cognitive or behavioral impairments and healthy controls. The primary outcome is the performance on the AROMHA Brain Health Test, which researchers will analyze to assess its potential as a predictive tool for neurodegenerative disease. Participation involves a single testing session lasting approximately one hour.

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD